96 related articles for article (PubMed ID: 1568218)
1. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.
Markaverich BM; Schauweker TH; Gregory RR; Varma M; Kittrell FS; Medina D; Varma RS
Cancer Res; 1992 May; 52(9):2482-8. PubMed ID: 1568218
[TBL] [Abstract][Full Text] [Related]
2. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth.
Markaverich BM; Gregory RR; Alejandro M; Kittrell FS; Medina D; Clark JH; Varma M; Varma RS
Cancer Res; 1990 Mar; 50(5):1470-8. PubMed ID: 2302712
[TBL] [Abstract][Full Text] [Related]
3. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
4. 2,6-Bis((3,4-dihydroxyphenyl)-methylene)cyclohexanone (BDHPC)-induced apoptosis and p53-independent growth inhibition: synergism with genistein.
Attalla H; Mäkelä TP; Wähälä K; Rasku S; Andersson LC; Adlercreutz H
Biochem Biophys Res Commun; 1997 Oct; 239(2):467-72. PubMed ID: 9344853
[TBL] [Abstract][Full Text] [Related]
5. Nuclear type-ii [h-3] estradiol binding-sites in mcf-7 human breast-cancer cells - binding interactions with 2,6-bis-([3,4-dihydroxyphenyl]-methylene)cyclohexanone esters and inhibition of cell-proliferation.
Markaverich B; Varma M; Densmore C; Tiller A; Schauweker T; Gregory R
Int J Oncol; 1994 Jun; 4(6):1291-300. PubMed ID: 21567051
[TBL] [Abstract][Full Text] [Related]
6. Type II estrogen binding site agonist: synthesis and biological evaluation of the enantiomers of methyl-para-hydroxyphenyllactate (MeHPLA).
Pretlow L; Williams R; Elliott M
Chirality; 2003 Oct; 15(8):674-9. PubMed ID: 12923805
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with a nuclear type-ii site agonist and 5-Fluorouracil - inhibition of mammary-tumor growth.
Markaverich B; Schauweker T; Gregory R; Varma R; Varma M; Kittrell F; Medina D
Int J Oncol; 1993 Mar; 2(3):385-92. PubMed ID: 21573566
[TBL] [Abstract][Full Text] [Related]
8. An endogenous inhibitor of [3H]estradiol binding to nuclear type II estrogen binding sites in normal and malignant tissues.
Markaverich BM; Roberts RR; Alejandro MA; Clark JH
Cancer Res; 1984 Apr; 44(4):1515-9. PubMed ID: 6704964
[TBL] [Abstract][Full Text] [Related]
9. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites.
Markaverich BM; Gregory RR; Alejandro MA; Clark JH; Johnson GA; Middleditch BS
J Biol Chem; 1988 May; 263(15):7203-10. PubMed ID: 3366774
[TBL] [Abstract][Full Text] [Related]
10. Nuclear type II [3H]estradiol binding site ligands: inhibition of ER-positive and ER-negative cell proliferation and c-Myc and cyclin D1 gene expression.
Markaverich BM; Shoulars K; Alejandro MA
Steroids; 2006 Oct; 71(10):865-74. PubMed ID: 16839579
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
12. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells.
Reiner GC; Katzenellenbogen BS; Bindal RD; Katzenellenbogen JA
Cancer Res; 1984 Jun; 44(6):2302-8. PubMed ID: 6547074
[TBL] [Abstract][Full Text] [Related]
13. Nuclear estradiol-binding sites in human breast cancer.
Vandewalle B; Peyrat JP; Bonneterre J; Hecquet B; Dewailly D; Lefebvre J
Cancer Res; 1983 Sep; 43(9):4497-503. PubMed ID: 6683589
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a unique nuclear estrogen-binding component in an estrogen-responsive mouse Leydig cell tumor.
Maeda Y; Sato B; Noma K; Kishimoto S; Koizumi K; Aono T; Matsumoto K
Cancer Res; 1983 Sep; 43(9):4091-7. PubMed ID: 6871850
[TBL] [Abstract][Full Text] [Related]
16. Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer.
Caltagirone S; Ranelletti FO; Rinelli A; Maggiano N; Colasante A; Musiani P; Aiello FB; Piantelli M
Am J Respir Cell Mol Biol; 1997 Jul; 17(1):51-9. PubMed ID: 9224209
[TBL] [Abstract][Full Text] [Related]
17. Estrogen binding sites in the nucleus of normal and malignant human tissue: characteristics of the multiple nuclear binding sites.
Syne JS; Markaverich BM; Clark JH; Panko WB
Cancer Res; 1982 Nov; 42(11):4449-54. PubMed ID: 7127287
[TBL] [Abstract][Full Text] [Related]
18. Effects of host hormonal status on binding of activated estrogen receptor to nuclei from R3230AC and 7,12-dimethylbenz[a]anthracene-induced mammary tumors.
Klinge CM; Bambara RA; Zain S; Hilf R
Cancer Res; 1989 Mar; 49(5):1165-70. PubMed ID: 2492902
[TBL] [Abstract][Full Text] [Related]
19. Selective increase in type II estrogen-binding sites in the dysplastic dorsolateral prostates of noble rats.
Ho SM; Yu M
Cancer Res; 1993 Feb; 53(3):528-32. PubMed ID: 7678774
[TBL] [Abstract][Full Text] [Related]
20. Partial purification and characterization of methyl-p-hydroxyphenyllactate esterase in rat uterine cytosol.
Maybruck WM; Markaverich BM
Steroids; 1997 Mar; 62(3):321-30. PubMed ID: 9071742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
